Longeveron (LGVN) Notes Payables (2021 - 2023)
Longeveron (LGVN) posted quarterly Notes Payables of $457000.0 for Q1 2023, down 73.9% quarter-over-quarter from $1.8 million in Q4 2022.
Longeveron (LGVN) Notes Payables (2021 - 2023) Analysis & Trends
Longeveron's Notes Payables history runs 3 years deep, the most recent figure standing at $457000.0 for Q1 2023.
- In Q1 2023, Notes Payables changed N/A year-over-year to $457000.0; the TTM figure through Mar 2023 stood at $457000.0 (changed N/A YoY), while the FY2022 annual figure was $1.8 million, up 171.47% from the prior year.
- Notes Payables for Q1 2023 stood at $457000.0, down from $1.8 million in the prior quarter.
- The five-year high for Notes Payables was $1.8 million in Q4 2022, with the low at $457000.0 in Q1 2023.
- The 3-year median for Notes Payables is $645000.0 (2021), against an average of $951000.0.
- Peak annual rise in Notes Payables reached 171.47% in 2022, while the deepest fall reached 171.47% in 2022.
- Longeveron's Notes Payables stood at $645000.0 in 2021, then soared by 171.47% to $1.8 million in 2022, then sank by 73.9% to $457000.0 in 2023.
- Business Quant data shows LGVN's Notes Payables at $457000.0 in Q1 2023, $1.8 million in Q4 2022, and $645000.0 in Q4 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 457,000.00 |
| Dec 31, 2022 | 1.75 Mn |
| Dec 31, 2021 | 645,000.00 |